CT-388
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Roche · Phase 3 · Recruiting · Enrollment 300
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Enicepatide Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Enicepatide Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Enicepatide Dose 3 | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.